Total Visits

Views
BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p)43

Select a period of time:

Views

Views
October 20240
November 20240
December 20240
January 20250
February 20250
March 202518
April 20254
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore18
Spain4
 

Top cities views

Views
Lugo3